Agoracom: Small Cap Investment - Mosaic ImmunoEngineering Inc.

No such message found

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Back To Forum List View

milestone

Rank: President [?]

Points: 18650 [?]

Votes: 158 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re '336, what happens next...

posted on Nov 28, 2007 02:20PM

Sec. 1.570 Issuance and publication of ex parte reexamination
certificate concludes ex parte reexamination proceeding.

    (a) To conclude an ex parte reexamination proceeding, the Director
will issue and publish an ex parte reexamination certificate in
accordance with 35 U.S.C. 307 setting forth the results of the ex parte
reexamination proceeding and the content of the patent following the ex
parte reexamination proceeding.
    (b) An ex parte reexamination certificate will be issued and
published in each patent in which an ex parte reexamination proceeding
has been ordered under Sec. 1.525 and has not been merged with any
inter partes reexamination proceeding pursuant to Sec. 1.989(a). Any
statutory disclaimer filed by the patent owner will be made part of the
ex parte reexamination certificate.
* * * * *
    (d) If an ex parte reexamination certificate has been issued and
published which cancels all of the claims of the patent, no further
Office proceedings will be conducted with that patent or any reissue
applications or any reexamination requests relating thereto.